**A genome-wide association study of IVGTT-based measures of first phase insulin secretion refines the underlying physiology of type 2 diabetes variants**

Mechanisms of type 2 diabetes genetic risk factors

Andrew R Wood1\*, Anna Jonsson2\*, Anne U Jackson3\*, Nan Wang4,5\*, Nienke van Leewen6\*, Nicholette D Palmer7, Sayuko Kobes8, Joris Deelen9, Lorena Boquete-Vilarino1, Jussi Paananen10, Alena Stančáková10, Dorret I Boomsma11, Eco JC de Geus11, Elisabeth MW Eekhoff12, Andreas Fritsche13,14,15, Mark Kramer12, Giel Nijpels16, Annemarie Simonis-Bik12, Timon W van Haeften17, Anubha Mahajan18, Michael Boehnke3, Richard N Bergman19, Jaakko Tuomilehto20,21,22,23, Francis S Collins24, Karen L Mohlke25, Karina Banasik2,18,26, Christopher J Groves27, Mark I McCarthy18,27,28, DIRECT, Ewan R Pearson29, Andrea Natali30, Andrea Mari31, Thomas A Buchanan4,5,32, Kent D Taylor33,34, Anny H Xiang35, Anette P. Gjesing2, Niels Grarup2, Hans Eiberg36, Oluf Pedersen2, Yii-Derr Chen33, Markku Laakso37, Jill M Norris38, Ulf Smith39, Lynne E Wagenknecht40, Leslie Baier8, Donald W Bowden7§, Torben Hansen2§, Mark Walker41§, Richard M Watanabe4,5,32§, Leen M ‘t Hart6,42,43§, Robert L Hanson8§, Timothy M Frayling1§

\*These authors contributed equally

**Affiliations**

1. Genetics of Complex Traits, Institute of Biomedical and Clinical Science, University of Exeter Medical School, Royal Devon and Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK

2. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

3. Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA

4. Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA USC

5. Diabetes and Obesity Research Institute, Keck School of Medicine of USC, Los Angeles, CA

6. Leiden University Medical Center, Department of Molecular Cell Biology, Leiden, the Netherlands

7. Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC

8. Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ

9. Max Planck Institute for Biology of Ageing, Cologne, Germany

10. Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland

11. Department of Biological Psychology, VU University, Amsterdam, The Netherlands

12. Internal Medicine-Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands.

13. Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, University of Tübingen, Germany.

14. Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Germany.

15. German Center for Diabetes Research (DZD e.V.), Tübingen, Germany.

16. Department of General Practice, EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands

17. Department of Internal Medicine, Utrecht University Medical Center, Utrecht, The Netherlands

18. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK

19. Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

20. Department of Health, National Institute for Health and Welfare, 00271 Helsinki, Finland

21. Dasman Diabetes Institute, Dasman, 15462 Kuwait

22. Department of Neuroscience and Preventive Medicine, Danube-University Krems, 3500 Krems, Austria

23. Saudi Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia

24. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA

25. Department of Genetics, University of North Carolina, Chapel Hill, NC 27599 USA

26. Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark

27. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK

28. Oxford National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, UK

29. School of Medicine, University of Dundee, Dundee, UK

30. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

31. Institute of Neuroscience, National Research Council, Padova, Italy

32. Department of Physiology & Biophysics, Keck School of Medicine of USC, Los Angeles, CA USC

33. Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA;

34. Department of Pediatrics, University of California Los Angeles, Los Angeles, CA

35. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 91107

36. Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.

37. Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

38. Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, CO

39. The Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

40. Wake Forest School of Medicine, Winston-Salem, NC 27157

41. Institute of Cellular Medicine, Newcastle University, UK

42. Leiden University Medical Center, Section of Molecular Epidemiology, Leiden, the Netherlands

43. VU University Medical Center, Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, Amsterdam, the Netherlands

**§ Corresponding Authors**

**Timothy M Frayling**

Genetics of Complex Traits,

University of Exeter Medical School,

University of Exeter, UK

+44 (0) 1392 408256

t.m.frayling@exeter.ac.uk

**Robert Hanson**

Diabetes Epidemiology and Clinical Research Section,

National Institute of Diabetes and Digestive and Kidney Diseases,

National Institutes of Health,

1550 East Indian School Road,

Phoenix, AZ 85014, United States.

602-200-5207

rhanson@phx.niddk.nih.gov

**Leen t’Hart**

Leiden University Medical Center,

Department of Molecular Cell Biology,

Leiden, The Netherlands

+31 71 5269796

lmthart@lumc.nl

**Richard Watanabe**

Keck School of Medicine of USC,

Departments of Preventive Medicine and Physiology & Biophysics;

Diabetes and Obesity Research Institute of USC;

Los Angeles, CA, 90033

323-442-2053

rwatanab@usc.edu

**Mark Walker**

Institute of Cellular Medicine

Newcastle University, UK

+44 (0) 191 208 7019

mark.walker@newcastle.ac.uk

**Torben Hansen**

Novo Nordisk Foundation Center for Basic Metabolic Research,

Section of Metabolic Genetics,

Faculty of Health and Medical Sciences,

University of Copenhagen, Copenhagen.

torben.hansen@sund.ku.dk

**Donald Bowden**

Department of Biochemistry

Wake Forest School of Medicine

Winston-Salem, NC USA

336-713-7507

dbowden@wfubmc.edu

Word Count: 4,173

Tables: 5

Figures: 4

**ABSTRACT**

Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 non-diabetic individuals from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycaemic traits and identify new loci. Thirty type 2 diabetes, or fasting glucose raising, alleles were associated with a measure of first phase insulin secretion at *P*<0.05, and provided new evidence, or the strongest evidence yet, that insulin secretion, intrinsic to the islet cells, is a key mechanism underlying the associations at the *HNF1A*, *IGFBP2*, *KCNQ1*, *HNF1B*, *VPS13C/C2CD4A*, *FAF1*, *PTPRD*, *AP3S2*, *KCNK16*, *MAEA*, *LPP, WFS1* and *TMPRSS6* loci. The fasting glucose raising allele near *PDX1*, a known key insulin transcription factor, was strongly associated with lower first phase insulin secretion but has no evidence for an effect on type 2 diabetes risk. The diabetes risk allele at *TCF7L2* was associated with a stronger effect on peak insulin response than on C-peptide-based insulin secretion rate, suggesting a possible additional role in hepatic insulin clearance or insulin processing. In summary, our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycaemic traits.

Common genetic variants associated with type 2 diabetes are more likely to be associated with insulin secretion than insulin resistance ([1](#_ENREF_1)). Studies of genetic variation and insulin secretion have been largely limited to fasting glucose or oral glucose tolerance test (OGTT)-based measures of beta-cell function and insulin secretion ([2](#_ENREF_2); [3](#_ENREF_3)). Oral-based measures of insulin secretion do not distinguish between mechanisms involving gut hormone signaling, e.g. incretin pathways, and mechanisms intrinsic to islet cell function or mass.

Compared to OGTT-based measures, intravenous-based measures provide a more accurate measure of first phase insulin secretion, with initial release of insulin peaking in the first five to ten minutes following glucose stimulation. Intravenous measures include the intravenous glucose tolerance test (IVGTT) and hyperglycaemic clamp. Family studies have shown that first phase insulin response, as measured by IVGTT is one of the most highly heritable glycaemic measures ([4-9](#_ENREF_4)), but genetic studies of intravenous-based measures of insulin secretion have examined limited numbers of variants or been performed in single studies ([8](#_ENREF_8); [10-14](#_ENREF_10)) with the exception of a recent meta-analysis performed in Hispanic Americans ([15](#_ENREF_15)).

Two studies have examined the effects of known type 2 diabetes variants in large meta-analyses of studies with OGTT data. A study of 23,443 individuals with OGTT-based measures of insulin secretion and insulin resistance, with a subset of 4,180 individuals with clamp-based measures of insulin resistance, examined 36 known type 2 diabetes variants. This study classified 16 variants into groups: nine were labelled as “beta-cell”, two as “hyperglycaemia”, four as “insulin resistance” and one as “insulin processing” (based on proinsulin measures) ([2](#_ENREF_2)). This analysis left 20 variants as “unclassified” which may include those that do not operate through these mechanisms as defined, or may reflect a lack of power to distinguish mechanisms when the type 2 diabetes risk effect is relatively weak. A second study performed a six-study genome-wide association study (GWAS) meta-analysis of OGTT-based measures of insulin secretion including the corrected insulin response (CIR; insulin response corrected to glucose at 30 mins during an OGTT) ([3](#_ENREF_3)). This study provided genome-wide data from 10,831 individuals and identified a signal in *GRB10* but otherwise did not identify any variants not previously identified as type 2 diabetes variants.

Here we performed a meta-analysis based GWAS of intraveneous-based measures of glucose stimulated insulin secretion. We used several measures of first phase insulin secretion with two aims - first, to refine the underlying physiology of known type 2 diabetes and glycaemic trait variants; second, to identify novel variants associated with first phase insulin secretion. Our study provides an advance to previous studies in several ways – first, it is the largest GWAS meta-analysis of intraveneous-based measures of glucose stimulated insulin secretion,; second, we used imputation from the 1000 Genomes Project to capture a wider range of genetic variation than previous GWAS of glycaemic traits, and third, we focused on characterizing the most recent lists of known type 2 diabetes and glycaemic trait variants. Using more than 5,500 individuals with intraveneous measures of first phase insulin secretion we show that most variants previously associated with insulin secretion, as measured by OGTT, operate through a primary islet cell-based mechanism and we provide new insight into the mechanisms of several variants where previous data had been unclear.

**RESEARCH DESIGN AND METHODS**

**Study samples**

The meta-analysis consisted of a total of 10 studies and a maximum of 5,567 individuals, with the full number available depending on the phenotype. These studies represented several different ethnic groups, with 3 studies of 2,346 Hispanic (IRASFS ([16](#_ENREF_16)), TRIPOD ([17](#_ENREF_17)), BETAGENE ([18](#_ENREF_18))), 6 studies of 2,900 individuals of European ancestry (EUGENE2 ([19](#_ENREF_19)), RISC ([20](#_ENREF_20)), Hyperglycemic clamp consortium (HCC) ([13](#_ENREF_13)), YOUTH92 ([21](#_ENREF_21)), FAMILY ([21](#_ENREF_21)) and FUSION ([22](#_ENREF_22))) and one study of 332 Pima Indians ([23](#_ENREF_23)). All studies were genotyped with a GWAS chip except the 413 HCC participants and a subset of 328 of 554 individuals from the FUSION study who were typed with the Metabochip ([24](#_ENREF_24)). Full descriptive characteristics, study design, sample size, sample quality control (QC) and intravenous measurement techniques for studies included are provided in **Supplementary Tables 1-3**. All participants provided written informed consent and the studies were approved by the respective Local Research Ethics committees or Institutional Review Boards.

**Phenotypes**

The ten studies each used a version of the IVGTT test. FUSION, Youth92, FAMILY and TRIPOD used tolbutamide-modified IVGTTs, IRASFS and BETAGENE insulin-modified IVGTTs. In the RISC study, the IVGTT was conducted at the end of an isoglycemic clamp as previously reported ([25](#_ENREF_25)).

In the HCC study, participants underwent a hyperglyceamic clamp after an overnight fast. After the priming glucose bolus, blood glucose was measured at 2 to 2.5 minute intervals and kept constant at 10 mmol/l for at least two hours via continuous variable glucose infusions ([13](#_ENREF_13)).

*Peak insulin response*

Peak insulin response was measured as peak insulin minus baseline insulin. The peak insulin time point was determined for each study, according to the time point having the highest average insulin value across all individuals.

*Acute insulin response*

Acute insulin response (AIR) was measured as the incremental area under the insulin curve during the first 10 minutes, or if a measure at 10 minutes was not available, during the first 8 minutes, using the trapezium equation ([26](#_ENREF_26)), with a minimum of insulin values at 0, 2, 4, 6, and 8 minutes during the IVGTT. Incremental insulin was calculated by subtracting the fasting insulin level.

*Insulin secretion rate*

Insulin secretion rate (ISR) was estimated from measured serum C-peptide concentrations at 0,2,4,6,8 (RISC) and 0, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 (FAMILY) minutes, using the ISEC software ([27](#_ENREF_27); [28](#_ENREF_28)), which calculates the secretion rate based on predefined C-peptide kinetic parameters from each individual’s weight, height, age, sex and clinical status (glucose tolerance and obesity status) determined in a population-based study ([29](#_ENREF_29); [30](#_ENREF_30)). ISR provides an estimate of the rate of insulin secretion prior to hepatic insulin clearance.

*Insulin sensitivity.*

We used the MINMOD software ([31](#_ENREF_31)) to calculate insulin sensitivity or a method suitable to the study (e.g. for Hyperglycaemic clamps see t’Hart et al. ([13](#_ENREF_13))).

*Disposition index*

Disposition index (DI) was calculated as the product of AIR and insulin sensitivity index calculated using the MINMOD software ([31](#_ENREF_31)). DI differs from peak insulin response and AIR because it is not a pure test of insulin secretion but takes into account the level of background insulin resistance.

*Oral glucose tolerance test measures of insulin secretion as a comparison*

Corrected insulin response (CIR) was based on oral glucose tolerance tests. To compare IVGTT-based results to OGTT-based results we calculated the CIR in a subset of 2,523 individuals from five of our studies. Calculation was the same as that used and described by Prokopenko et al. : Corrected Insulin Response (CIR) = (100 x insulin at 30 min)/(glucose at 30 min x (glucose at 30 min–3.89)) ([3](#_ENREF_3)).

**Genotyping and imputation**

*Genotyping and imputation within studies*

Details on the genotyping platform used and genotype quality control procedures employed for each study are presented in **Supplementary Table 3**. All GWAS cohorts were genotyped using commercially available Affymetrix (Affymetrix, Inc., Santa Clara, CA, USA), or Illumina (Illumina, Inc. San Diego, CA, USA) genotyping arrays. To facilitate meta-analyses for each trait, studies performed genotype imputation using MACH ([32](#_ENREF_32)), MINIMAC ([33](#_ENREF_33)), or IMPUTE ([34](#_ENREF_34)) to impute up to a common set of variants. All studies (except the Pima study) imputed up to ~39M SNPs and indels from 2184 haplotypes available from the 1000 Genomes Project Phase 1 - version 3 ([35](#_ENREF_35))). Due to the relative difference in ancestry between the Pima cohort and the samples within the 1000 Genomes reference panel, imputation in Pima was based on 532 haplotypes derived from whole-genome sequencing efforts within the Pima study.

*Metabochip genotyping*

Additional studies genotyped on the Illumina Metabochip without subsequent imputation but with available phenotype data were also incorporated into the meta-analysis. Details of these studies can be found in **Supplementary Tables 1-3**.

**Statistical analysis**

*Phenotype Transformations*

Each trait was adjusted for age, sex, and study specific covariates as necessary (**Supplementary Table 2**) by adding them to a regression model and using the residuals as the phenotype. We then inverse normalized this residualised phenotype to create a normal distribution. This process is important to reduce false positive results when testing 1000s of rarer variants. Analyses were repeated adjusting for BMI and insulin sensitivity. To account for population stratification, studies also adjusted for principal components or if running association testing outside of a linear-mixed model framework.

*Association analysis*

Additive association analysis for each trait was carried out using MACH2QTL ([32](#_ENREF_32)), SOLAR (for IRASFS) or using linear mixed models as implemented in EMMAX ([36](#_ENREF_36)), GEMMA ([37](#_ENREF_37)) or QTassoc ([38](#_ENREF_38)) (**Supplementary Table 3**). For each trait and adjustment combination, we performed a fixed effects meta-analysis based on standard errors, as implemented in Metal [http://csg.sph.umich.edu/abecasis/Metal]. We applied a variant minor allele count (MAC) filter of MAC>5 and genomic control correction to the input files prior to meta-analysis. Variants with a meta-analysis *P*-value <5×10-8 were considered to be genome-wide significant. All genome-wide statistics are available on our website (url: http://www.t2diabetesgenes.org/data/)*.*

**Selection of known variants and previous traits**

*Type 2 diabetes*

We selected 76 variants identified by GWAS as associated with type 2 diabetes. For European studies these were based on a GWAS+Metabochip meta-analysis of 34,840 cases and 114,981 controls ([39](#_ENREF_39)) and for non-Europeans this included variants at GWAS significance across a trans-ethnic study meta-analysis of 26,488 cases and 83,964 controls ([40](#_ENREF_40)).

*Glycaemic and insulin related traits*

We selected variants representing 65 signals listed in the supplementary or main tables of Prokopenko et al. ([3](#_ENREF_3)) as associated with a glycaemic or insulin related trait, including fasting glucose, fasting insulin, 2-hour insulin, HbA1C, and proinsulin. We also selected an additional 5 variants associated with fasting glycaemic traits identified by an earlier meta-analysis that fell 250kb outside of the 65 signals ([41](#_ENREF_41)).

**RESULTS**

*Several variants are associated with intravenous-based measures of first phase insulin secretion at genome-wide significance, including MTNR1B and CDKAL1.*

Results are represented in tables 1-5 and figures 1-4. The two strongest association signals represented known type 2 diabetes loci, those in or near *MTNR1B* and *CDKAL1* (**Table 1**). The known signal at *MTNR1B* was associated with peak insulin response (*P*=1.3×10-24), AIR (*P*=3.7×10-21) and DI (*P*=3.3×10-17), and *CDKAL1* with peak insulin response (*P*=1.5×10-12) and AIR (*P*=1.5×10-9). The peak insulin and AIR results were very similar after adjusting for BMI and/or SI **(Supplementary Table 4**). In addition, we identified a few novel genome-wide associations that require further validation and replication - these associations were either rare variants (*REG3G*), only present in a specific ethnic group (*CHST1*) or sensitive to covariates used (*BLVRA/MRPS24*) (**Supplementary Table 5**). We tested these novel variants for an association with type 2 diabetes in the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) GWAS ([40](#_ENREF_40)) but none of the SNPs were associated with type 2 diabetes at *P*<0.05.

*Twenty-one known type 2 diabetes risk alleles are associated with lower first phase insulin response*

Of 76 type 2 diabetes known risk alleles, 21 were associated (at *P*<0.05) with reduced first phase insulin secretion as measured by peak insulin response or acute insulin response (17 variants were associated with both peak insulin and AIR at *P*<0.05) (**Table 1**). Peak Insulin and AIR associations tended to be very similar for all variants (**Table 1**). This number of risk alleles associated with reduced insulin secretion at *P*<0.05 is far more than the 2-3 expected by chance. Three additional type 2 diabetes risk alleles were associated with higher first phase insulin response and these are discussed below [*NOTCH2*, *PPARG* and *GCC1*]. Results were similar when adjusting for BMI and insulin sensitivity (**Supplementary Table 4**). These 21 variants included 10 previously classified as having a clear role in insulin secretion - eight were previously classified as “beta-cell”, one as “hyperglycaemia” (*MTN1RB*) and one as “insulin processing” (*ARAP1/STARD10*) ([2](#_ENREF_2)). We did not detect any evidence that the variant previously labelled as “beta-cell” in the *THADA* gene was associated with first phase insulin response. We were not able to account for the potential parent of origin effect at THADA ([42](#_ENREF_42)), but neither were the previous largest OGTT-based studies. Of the eleven other variants we detected, those in the *HNF1A*, *IGFBP2*, *KCNQ1* genes had previously been associated with at least one measure of insulin secretion or fasting glucose, and our data now strengthens the evidence that these variants increase type 2 diabetes risk through an insulin secretory mechanism including lower first phase insulin response. Our findings provide new evidence that type 2 diabetes variants in the loci labelled as in or near the *HNF1B*, *VPS13C/C2CD4A*, *FAF1*, *PTPRD*, *AP3S2*, *KCNK16*, *MAEA* and *LPP* genes alter type 2 diabetes risk through mechanisms that include first phase insulin secretion. Although none of these eight reached Bonferroni corrected levels of significance, we would only expect 2-3 of 76 type 2 diabetes risk alleles to be associated with lower insulin secretion at *P*<0.05, suggesting most of these eight variants operate through insulin secretion mechanisms (**Table 1)**.

*Six variants associated with higher fasting glucose but not type 2 diabetes, are associated with lower first phase insulin secretion.*

We next examined 70 known variants associated with intermediate glycaemic traits. These traits consisted of those analysed by the Meta-Analysis of Glucose and Insulin Consortium (MAGIC) and included fasting glucose and insulin, proinsulin, HbA1c, and 2-hour post-OGTT glucose levels. These variants partially overlap those associated with type 2 diabetes. We identified 6 variants not in the type 2 diabetes list where the fasting glucose raising allele was associated with first phase insulin secretion before (**Table 2)** and after correcting for BMI and insulin sensitivity **(Supplementary Table 6**). Fasting glucose raising alleles in or near the *PDX1*, *DNLZ*, *CRY2*, *GLIS3*, *PROX1* and *ADRA2A* genes were associated with lower first phase insulin secretion at *P*<0.05. We next examined published data from the DIAGRAM consortium to establish whether or not these alleles were associated with type 2 diabetes but had not reached genome-wide significance – only the allele at *PDX1* was not nominally associated with type 2 diabetes (*P*>0.05) in Morris et al. ([39](#_ENREF_39)). All five of the other alleles associated with higher fasting glucose and lower first phase insulin were associated with a higher risk of type 2 diabetes with *P*-values of 0.03 (*CRY2*, Odds ratio (OR) 1.03), 0.001 (*ADRA2A* OR 1.06), 0.0001 (*GLIS3* OR 1.04), 0.0001 (*DNLZ* OR 1.06) and 1×10-7 (*PROX1* OR 1.06) ([39](#_ENREF_39)).

*Ten**known type 2 diabetes or glycaemic trait alleles are associated with lower insulin secretion rate*

For a subset of 1,268 non-diabetic individuals we had a measure of insulin secretion rate by C-peptide deconvolution ([27](#_ENREF_27); [30](#_ENREF_30)). For ten known variants, the type 2 diabetes or glycaemic trait risk allele was associated with lower insulin secretion rate at *P*<0.05. These analyses highlighted two variants that had no clear underlying physiological profile based on previous OGTT data or our own peak insulin response or AIR analyses – those in *WFS1* and *TMPRSS6* (**Table 3**).Of these ten variants previously associated with a glycaemic trait and associated with insulin secretion rate in our study, two were not known type 2 diabetes variants – those in *TMPRSS6* (HbA1C raising allele associated with lower ISR) and *PDX1* (fasting glucose raising allele associated with lower ISR). The *TMPRSS6* allele, like the *PDX1* allele, was not nominally associated with type 2 diabetes in the DIAGRAM study (*P*>0.05).

*Sixteen variants where the type 2 diabetes risk allele is apparently paradoxically associated with higher insulin secretion or insulin secretion rates.*

We identified sixteen variants with apparently paradoxical effects on type 2 diabetes risk, glycaemic traits, and first phase insulin secretion or insulin secretion rate. These included three (*PPARG*, *FTO,* *TET2*) with known primary effects on insulin resistance ([43](#_ENREF_43)) or BMI and three (*ARAP1*, *PCSK1*, *MADD*) ([44](#_ENREF_44)) with known primary effects on proinsulin. Whilst the effects on insulin secretion were similar when correcting for insulin resistance and BMI the associations with disposition index tended to be weaker (**Tables 4** and **5**).

**DISCUSSION**

By performing a large genome-wide association study of first phase IVGTT-based insulin secretion we provide new insights into the likely mechanisms by which some of the known type 2 diabetes and glycaemic trait variants affect glucose homeostasis. Our results complement those from OGTT-derived measures of insulin secretion and emphasize the need to consider first phase, second phase and C-peptide derived measures of insulin secretion as well as insulin resistance when considering the likely function of type 2 diabetes associated alleles. We provide details of 178 previously described associations in supplementary table 8. We did not identify any robust associations between new variants and IVGTT-based measures of insulin secretion and so we focus this discussion on the known variants. The lack of novel variants is perhaps not surprising given the large studies of type 2 diabetes performed and relative power, and the likelihood that any variant with a strong effect on first phase insulin secretion is likely to have been associated with type 2 diabetes, or an OGTT-based measure of insulin secretion. Previous family studies have also shown strong genetic overlaps between OGTT-derived CIR and IVGTT-derived AIR ([45](#_ENREF_45)).

*Known type 2 diabetes risk alleles are associated with lower first phase insulin secretion in response to IV glucose.*

We found that 21 of the alleles previously associated with higher type 2 diabetes risk are also associated with lower insulin secretion during IVGTT at *P*<0.05. Associations were similar with disposition index, which corrects for insulin sensitivity. Those with the strongest effects, and the only ones reaching genome-wide significance, were those in or near the *MTNR1B* and *CDKAL1* genes. In addition to classifications based on OGTT-derived measures ([2](#_ENREF_2)), we can now also classify a number of previously unclassified loci as being involved in beta-cell function. These include *IGF2BP2*, *C2CD4A*, *FAF1*, *PTPRD*, *AP3S2*, *NF1B*, *MAEA*, *KCNK16*, and *LPP*. Of the nine variants previously labeled as “beta-cell” by Dimas et al., eight were associated with first phase insulin secretion, the exception being that in the *THADA* gene. Based on the analysis of Dimas et al., this variant is more likely to operate on fasting glucose rather than stimulated glucose tolerance.

*A common allele upstream of PDX1 is associated with higher fasting glucose and lower first phase insulin secretion but not type 2 diabetes.*

We identified six alleles that were associated with lower first phase insulin secretion that were previously associated with higher fasting glucose levels but were not associated, at genome-wide significance, with type 2 diabetes risk. These include those in or near *PDX1*, *DNLZ*, *CRY2*, *GLIS3*, *PROX1* and *ADRA2A* genes. Five of these six variants are nominally associated with type 2 diabetes risk in the expected direction. The exception is the allele ~6.6kb upstream of *PDX1,* a gene in which mutations cause maturity onset diabetes of the young ([46](#_ENREF_46)). This allele has the third strongest association with first phase insulin secretion in our study, after those in *MTNR1B* and *CDKAL1*, and ahead of those in known type 2 diabetes loci such as *TCF7L2*, *SLC30A8*, *IGF2BP2*, *CDKN2A/B* and *HHEX/IDE*, but was not associated with type 2 diabetes in the most recent, multi-ethnic, type 2 diabetes study of 26,488 cases and 83,964 controls. One explanation for this apparently paradoxical association is that the *PDX1* allele causes a stable resetting of glucose tolerance but does not lead to deterioration in beta cell function, as is seen in MODY2. We also note that it is not associated with oral-based measures of insulin secretion ([3](#_ENREF_3)).

*Variants with apparently paradoxical effects on type 2 diabetes risk, glycaemic traits and first phase insulin secretion.*

We identified 16 variants with an apparently paradoxical effect on at least one measure of insulin secretion and type 2 diabetes risk – the type 2 diabetes risk allele was associated with higher insulin secretion. Many of these associations were much weaker when using disposition index rather than peak insulin or acute insulin response, suggesting the association with higher insulin secretion is a compensatory mechanism for higher background insulin resistance (*FTO*, *PPARG*) ([43](#_ENREF_43)) or less efficient insulin processing (*MADD*, *ARAP1*, *PSCK1*) ([44](#_ENREF_44)). The exceptions were the alleles in *GRB10* and *G6PC2*, where correcting for insulin resistance or using disposition index did not appreciably weaken the association. At both these loci, previous studies have noted the paradoxical associations between the allele associated with higher fasting glucose and higher OGTT-based insulin secretion ([3](#_ENREF_3)). It was also previously shown that the effect of the *G6PC2* gene was dependent on glycaemia which may explain these apparent paradoxical results and suggest that effects of hyperglycemia may override genetic effects observed in healthy volunteers ([47](#_ENREF_47)).

*Known type 2 diabetes or glycaemic trait alleles associated with lower insulin secretion rate*

For a subset of 1,268 non-diabetic individuals we had a measure of insulin secretion rate by C-peptide deconvolution, a measure of insulin secretion that accounts for hepatic insulin clearance ([29](#_ENREF_29); [30](#_ENREF_30)). Eighteen known variants were nominally associated with insulin secretion rate at *P*<0.05 – 10 where the type 2 diabetes or glycaemic trait risk allele was associated with lower insulin secretion rate, and 8 where the risk allele was associated with higher insulin secretion rate. These analyses highlighted two variants that had no clear underlying physiological profile based on previous data or our own peak insulin response or AIR analyses, those in *WFS1* and *TMPRSS6,* although one large study had shown the *WFS1* allele as associated with oral-based measures of insulin secretion ([48](#_ENREF_48)). The statistical confidence of these associations was not strong and further studies are needed to confirm them. The diabetes risk alleles associated with higher insulin secretion rate are either likely to reflect the need for higher insulin secretion to remain non-diabetic given a primary effect on insulin resistance (e.g. *HMGA2*) or insulin processing (e.g. *PCSK1*), or need further data to support the findings.

*Alleles with disproportionate effects on different traits.*

We compared the effects of known variants across different traits (**Fig. 1-4**). Previous studies have highlighted that some known type 2 diabetes variants appear to have disproportionately small or large effects on type 2 diabetes risk compared to their effects on fasting glucose or insulin secretion ([2](#_ENREF_2)). Here we highlight how measures of first phase insulin secretion help refine these comparisons. Several variants are noteworthy. First, our most notable finding is that of the common variant 6kb upstream of *PDX1* which is the third most strongly associated locus with first phase insulin secretion (peak insulin) but there is no evidence it affects type 2 diabetes risk even in the latest very large type 2 diabetes case control study ([40](#_ENREF_40)). Unlike the alleles in or near *G6PC2* and *GRB10*, the allele at *PDX1* associated with lower insulin secretion and was also associated with higher fasting glucose. Second, the common variant in *TCF7L2* appears to have a disproportionately small effect on first phase insulin secretion in response to IV glucose given its effect on type 2 diabetes and in comparison to other variants. This observation is consistent with the effect of this variant on OGTT-based measures of insulin secretion ([2](#_ENREF_2)). There is emerging evidence that *TCF7L2* influences diabetes risk through mechanisms involving multiple tissues ([49-52](#_ENREF_49)), including a possible role on hepatic glucose production ([53](#_ENREF_53)) in addition to direct effects at the pancreatic beta-cell ([49](#_ENREF_49); [52](#_ENREF_52)). One possibility is that the *TCF7L2* risk allele also affects insulin clearance, a possibility consistent with our observation that the allele has a weaker effect on insulin secretion rate, (that uses C-peptide as the main measure of insulin secretion, and so excludes any effects on hepatic insulin clearance from the insulin secretion measure) than peak insulin response (**Fig. 3 & 4**). Another possibility is that the effect of the *TCF7L2* risk allele on diabetes risk additionally depends on impaired incretin action ([54](#_ENREF_54); [55](#_ENREF_55)) and impaired proinsulin processing ([56](#_ENREF_56); [57](#_ENREF_57)), mechanisms not directly assessed in the present study. Third, our data are also consistent with previous data on OGTT-based measures that show the variant at *MTN1RB* has a disproportionately large effect on insulin secretion and fasting glucose levels compared to its effect on type 2 diabetes, possibly as a result of an additional effect on insulin action ([58](#_ENREF_58)).

Our study had several strengths and limitations. Although our sample size of ~5,500 subjects is modest relative to previous OGTT-based measures, we have used the largest sample size yet for an intravenous-based measure of insulin secretion. Furthermore, we have characterised the most recent catalogue of variants associated with type 2 diabetes and glycaemic traits.

The limitations were that we had a mixed ancestry set of studies, although results in Europeans were very similar, suggesting that the known common variants have limited, if any, heterogeneous effects across different ethnic groups. Some of the associations we observed only reached nominal levels of statistical confidence, and further analyses are needed, ideally in even larger sample sizes, to characterize the approximately 50% of known variants with no clear mechanism.

In conclusion, our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycaemic traits, and it further supports the notion that many established genetic variants for type 2 diabetes risk confer increased risk through an effect on beta-cell function.

**ACKNOWLEDGEMENTS**

D.W.B., T.M.F., T.H., R.L.H., L.M.t.H., A.Jackson, A.Jonsson, N.v.L, N.W., M.W., R.M.W., and A.R.W. designed the study. L.Boquete-Vilarino, J.D., A.P.G, A.Jackson, A.Jonsson, N.v.L, N.D.P., J.P., N.W., and A.R.W. performed study-specific data processing and analyses. A.Jackson, A.Jonsson, N.v.L., N.W., and A.R.W. performed central processing and statistical analysis of the study-specific analyses provided. L.Baier, K.B., D.I.B., D.W.B., T.A.B., Y.C., M.E.M.W.E., H.E., T.M.F., A.F., N.G., E.J.C.d.G., C.J.G., T.W.v.H., L.M.t.H., T.H., R.L.H., S.K., M.K., M.L., A.Mahajan, M.B., R.N.B., J.T., F.S.C., K.L.M., A.Mari, M.I.M., A.N., G.N., J.M.N., E.R.P., O.P., A.Simonis-Bik, U.S., A.Stančáková, K.D.T., L.E.W., M.W., R.M.W., and A.H.X. assisted in the provision of study-specific data prior to statistical analysis. T.M.F., T.H., R.L.H., L.M.t.H., A.Jackson, A.Jonsson, N.v.L., M.W., N.W., R.M.W., A.R.W. and were involved in co-writing the first manuscript draft. D.I.B, T.A.B, A.M., A.N, and N.D.P. commented and edited drat manuscript.

T.M.F. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

A.F., A.H.X., A.Jackson, A.Jonsson, A.Mahajan, A.Mari, A.N., A.P.G, A.R.W., A.Simonis-Bik, A.Stančáková, C.J.G., D.I.B., D.W.B., E.J.C.d.G., E.M.W.E., E.R.P., F.S.C., G.N., H.E., J.D., J.M.N., J.P., J.T., K.B., K.D.T., K.L.M., L.Baier, L.Boquete-Vilarino, L.E.W., L.M.t.H., M.B., M.I.M., M.K., M.L., M.W., N.D.P., N.G., N.v.L., N.W., O.P., R.L.H., R.N.B., R.M.W., S.K., T.A.B., T.H., T.M.F., T.W.v.H., U.S., and Y.C. declare no conflict of interest.

A.R.W. and T.M.F. are supported by a European Research Council grant (SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC). R.L.H., S.K. and L. Baier are supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. This work was in part funded by the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115317 (DIRECT), resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind contribution (<http://www.direct-diabetes.org/>); the Netherlands Organization for Health Research and Development (Priority Medicines Elderly Program 113102006); The Netherlands Twin Register, part of the HCC cohort, is supported by the European Research Council (grant 230374), by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007) and the Netherlands Organization for Scientific Research (grant NWO 480-04-004, NWO/SPI 56-464-14192). The RISC Study was supported by European Union grant QLG1-CT-2001-01252 and AstraZeneca. The initial genotyping of the RISC samples was funded by Merck & Co Inc. This research was supported by the National Institutes of Health: IRASFS (HL060944, HL061019, HL060919, and HG007112) and the GUARDIAN Consortium (DK085175). The provision of genotyping data was supported in part by UL1-TR-000124 (Clinical and Translational Science Institute) and DK063491. Computing resources were provided in part by the Wake Forest School of Medicine Center for Public Health Genomics. Support for FUSION was provided by NIH grants R01-DK062370 (to M.B.), R01-DK072193 (to K.L.M.), and intramural project number 1Z01-HG000024 (to F.S.C.). Genotyping was conducted by the Johns Hopkins University Genetic Resources Core Facility SNP Center at the Center for Inherited Disease Research (CIDR), with support from CIDR NIH contract no. N01-HG-65403.

**REFERENCES**

1. Perry JR, Frayling TM: New gene variants alter type 2 diabetes risk predominantly through reduced beta-cell function. Curr Opin Clin Nutr Metab Care 2008;11:371-377

2. Dimas AS, Lagou V, Barker A, Knowles JW, Magi R, Hivert MF, Benazzo A, Rybin D, Jackson AU, Stringham HM, Song C, Fischer-Rosinsky A, Boesgaard TW, Grarup N, Abbasi FA, Assimes TL, Hao K, Yang X, Lecoeur C, Barroso I, Bonnycastle LL, Bottcher Y, Bumpstead S, Chines PS, Erdos MR, Graessler J, Kovacs P, Morken MA, Narisu N, Payne F, Stancakova A, Swift AJ, Tonjes A, Bornstein SR, Cauchi S, Froguel P, Meyre D, Schwarz PE, Haring HU, Smith U, Boehnke M, Bergman RN, Collins FS, Mohlke KL, Tuomilehto J, Quertemous T, Lind L, Hansen T, Pedersen O, Walker M, Pfeiffer AF, Spranger J, Stumvoll M, Meigs JB, Wareham NJ, Kuusisto J, Laakso M, Langenberg C, Dupuis J, Watanabe RM, Florez JC, Ingelsson E, McCarthy MI, Prokopenko I, Investigators M: Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 2014;63:2158-2171

3. Prokopenko I, Poon W, Magi R, Prasad BR, Salehi SA, Almgren P, Osmark P, Bouatia-Naji N, Wierup N, Fall T, Stancakova A, Barker A, Lagou V, Osmond C, Xie W, Lahti J, Jackson AU, Cheng YC, Liu J, O'Connell JR, Blomstedt PA, Fadista J, Alkayyali S, Dayeh T, Ahlqvist E, Taneera J, Lecoeur C, Kumar A, Hansson O, Hansson K, Voight BF, Kang HM, Levy-Marchal C, Vatin V, Palotie A, Syvanen AC, Mari A, Weedon MN, Loos RJ, Ong KK, Nilsson P, Isomaa B, Tuomi T, Wareham NJ, Stumvoll M, Widen E, Lakka TA, Langenberg C, Tonjes A, Rauramaa R, Kuusisto J, Frayling TM, Froguel P, Walker M, Eriksson JG, Ling C, Kovacs P, Ingelsson E, McCarthy MI, Shuldiner AR, Silver KD, Laakso M, Groop L, Lyssenko V: A central role for GRB10 in regulation of islet function in man. PLoS genetics 2014;10:e1004235

4. Gjesing AP, Hornbak M, Allin KH, Ekstrom CT, Urhammer SA, Eiberg H, Pedersen O, Hansen T: High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients. Diabetologia 2014;57:1173-1181

5. Hu C, Zhang R, Wang C, Wang J, Ma X, Hou X, Lu J, Yu W, Jiang F, Bao Y, Xiang K, Jia W: Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS One 2010;5:e15542

6. Rich SS, Bowden DW, Haffner SM, Norris JM, Saad MF, Mitchell BD, Rotter JI, Langefeld CD, Wagenknecht LE, Bergman RN, Insulin Resistance Atherosclerosis Study Family S: Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2004;53:1866-1875

7. Sakul H, Pratley R, Cardon L, Ravussin E, Mott D, Bogardus C: Familiality of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians. American journal of human genetics 1997;60:651-656

8. Simonis-Bik AM, Nijpels G, van Haeften TW, Houwing-Duistermaat JJ, Boomsma DI, Reiling E, van Hove EC, Diamant M, Kramer MH, Heine RJ, Maassen JA, Slagboom PE, Willemsen G, Dekker JM, Eekhoff EM, de Geus EJ, t Hart LM: Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 2010;59:293-301

9. Staiger H, Machicao F, Schafer SA, Kirchhoff K, Kantartzis K, Guthoff M, Silbernagel G, Stefan N, Haring HU, Fritsche A: Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One 2008;3:e3962

10. Rich SS, Goodarzi MO, Palmer ND, Langefeld CD, Ziegler J, Haffner SM, Bryer-Ash M, Norris JM, Taylor KD, Haritunians T, Rotter JI, Chen YD, Wagenknecht LE, Bowden DW, Bergman RN: A genome-wide association scan for acute insulin response to glucose in Hispanic-Americans: the Insulin Resistance Atherosclerosis Family Study (IRAS FS). Diabetologia 2009;52:1326-1333

11. Palmer ND, Langefeld CD, Ziegler JT, Hsu F, Haffner SM, Fingerlin T, Norris JM, Chen YI, Rich SS, Haritunians T, Taylor KD, Bergman RN, Rotter JI, Bowden DW: Candidate loci for insulin sensitivity and disposition index from a genome-wide association analysis of Hispanic participants in the Insulin Resistance Atherosclerosis (IRAS) Family Study. Diabetologia 2010;53:281-289

12. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, Maassen JA, Machicao F, Schafer SA, Haring HU, t Hart LM, van Haeften TW: Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 2008;51:1659-1663

13. t Hart LM, Simonis-Bik AM, Nijpels G, van Haeften TW, Schafer SA, Houwing-Duistermaat JJ, Boomsma DI, Groenewoud MJ, Reiling E, van Hove EC, Diamant M, Kramer MH, Heine RJ, Maassen JA, Kirchhoff K, Machicao F, Haring HU, Slagboom PE, Willemsen G, Eekhoff EM, de Geus EJ, Dekker JM, Fritsche A: Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion during hyperglycemic clamps. Diabetes 2010;59:287-292

14. van Vliet-Ostaptchouk JV, van Haeften TW, Landman GW, Reiling E, Kleefstra N, Bilo HJ, Klungel OH, de Boer A, van Diemen CC, Wijmenga C, Boezen HM, Dekker JM, van 't Riet E, Nijpels G, Welschen LM, Zavrelova H, Bruin EJ, Elbers CC, Bauer F, Onland-Moret NC, van der Schouw YT, Grobbee DE, Spijkerman AM, van der AD, Simonis-Bik AM, Eekhoff EM, Diamant M, Kramer MH, Boomsma DI, de Geus EJ, Willemsen G, Slagboom PE, Hofker MH, t Hart LM: Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. PLoS One 2012;7:e32148

15. Palmer ND, Goodarzi MO, Langefeld CD, Wang N, Guo X, Taylor KD, Fingerlin TE, Norris JM, Buchanan TA, Xiang AH, Haritunians T, Ziegler JT, Williams AH, Stefanovski D, Cui J, Mackay AW, Henkin LF, Bergman RN, Gao X, Gauderman J, Varma R, Hanis CL, Cox NJ, Highland HM, Below JE, Williams AL, Burtt NP, Aguilar-Salinas CA, Huerta-Chagoya A, Gonzalez-Villalpando C, Orozco L, Haiman CA, Tsai MY, Johnson WC, Yao J, Rasmussen-Torvik L, Pankow J, Snively B, Jackson RD, Liu S, Nadler JL, Kandeel F, Chen YD, Bowden DW, Rich SS, Raffel LJ, Rotter JI, Watanabe RM, Wagenknecht LE: Genetic Variants Associated With Quantitative Glucose Homeostasis Traits Translate to Type 2 Diabetes in Mexican Americans: The GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium. Diabetes 2015;64:1853-1866

16. Henkin L, Bergman RN, Bowden DW, Ellsworth DL, Haffner SM, Langefeld CD, Mitchell BD, Norris JM, Rewers M, Saad MF, Stamm E, Wagenknecht LE, Rich SS: Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol 2003;13:211-217

17. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA: TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Controlled clinical trials 1998;19:217-231

18. Watanabe RM, Allayee H, Xiang AH, Trigo E, Hartiala J, Lawrence JM, Buchanan TA: Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 2007;56:1481-1485

19. Staiger H, Stancakova A, Zilinskaite J, Vanttinen M, Hansen T, Marini MA, Hammarstedt A, Jansson PA, Sesti G, Smith U, Pedersen O, Laakso M, Stefan N, Fritsche A, Haring HU: A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 2008;57:514-517

20. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E, Group E-RS: The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 2004;47:566-570

21. Hansen T, Ambye L, Grarup N, Hansen L, Echwald SM, Ferrer J, Pedersen O: Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus. Diabetologia 2001;44:1330-1334

22. Valle T, Tuomilehto J, Bergman RN, Ghosh S, Hauser ER, Eriksson J, Nylund SJ, Kohtamaki K, Toivanen L, Vidgren G, Tuomilehto-Wolf E, Ehnholm C, Blaschak J, Langefeld CD, Watanabe RM, Magnuson V, Ally DS, Hagopian WA, Ross E, Buchanan TA, Collins F, Boehnke M: Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes care 1998;21:949-958

23. Hanson RL, Muller YL, Kobes S, Guo T, Bian L, Ossowski V, Wiedrich K, Sutherland J, Wiedrich C, Mahkee D, Huang K, Abdussamad M, Traurig M, Weil EJ, Nelson RG, Bennett PH, Knowler WC, Bogardus C, Baier LJ: A genome-wide association study in American Indians implicates DNER as a susceptibility locus for type 2 diabetes. Diabetes 2014;63:369-376

24. Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, Chines PS, Burtt NP, Fuchsberger C, Li Y, Erdmann J, Frayling TM, Heid IM, Jackson AU, Johnson T, Kilpelainen TO, Lindgren CM, Morris AP, Prokopenko I, Randall JC, Saxena R, Soranzo N, Speliotes EK, Teslovich TM, Wheeler E, Maguire J, Parkin M, Potter S, Rayner NW, Robertson N, Stirrups K, Winckler W, Sanna S, Mulas A, Nagaraja R, Cucca F, Barroso I, Deloukas P, Loos RJ, Kathiresan S, Munroe PB, Newton-Cheh C, Pfeufer A, Samani NJ, Schunkert H, Hirschhorn JN, Altshuler D, McCarthy MI, Abecasis GR, Boehnke M: The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS genetics 2012;8:e1002793

25. Mari A, Tura A, Natali A, Anderwald C, Balkau B, Lalic N, Walker M, Ferrannini E, Investigators R: Influence of hyperinsulinemia and insulin resistance on in vivo beta-cell function: their role in human beta-cell dysfunction. Diabetes 2011;60:3141-3147

26. Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990;300:230-235

27. Hovorka R, Soons PA, Young MA: ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996;50:253-264

28. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, Van Cauter E: Quantitative study of insulin secretion and clearance in normal and obese subjects. The Journal of clinical investigation 1988;81:435-441

29. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA: Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 1998;41:548-554

30. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377

31. Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986;23:113-122

32. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR: MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genetic epidemiology 2010;34:816-834

33. Fuchsberger C, Abecasis GR, Hinds DA: minimac2: faster genotype imputation. Bioinformatics 2015;31:782-784

34. Howie BN, Donnelly P, Marchini J: A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS genetics 2009;5:e1000529

35. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR: A global reference for human genetic variation. Nature 2015;526:68-74

36. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, Sabatti C, Eskin E: Variance component model to account for sample structure in genome-wide association studies. Nature genetics 2010;42:348-354

37. Zhou X, Stephens M: Genome-wide efficient mixed-model analysis for association studies. Nature genetics 2012;44:821-824

38. Uh HW, Beekman M, Meulenbelt I, Houwing-Duistermaat JJ: Genotype-Based Score Test for Association Testing in Families. Statistics in biosciences 2015;7:394-416

39. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, Lindgren CM, Muller-Nurasyid M, Pechlivanis S, Rayner NW, Scott LJ, Wiltshire S, Yengo L, Kinnunen L, Rossin EJ, Raychaudhuri S, Johnson AD, Dimas AS, Loos RJ, Vedantam S, Chen H, Florez JC, Fox C, Liu CT, Rybin D, Couper DJ, Kao WH, Li M, Cornelis MC, Kraft P, Sun Q, van Dam RM, Stringham HM, Chines PS, Fischer K, Fontanillas P, Holmen OL, Hunt SE, Jackson AU, Kong A, Lawrence R, Meyer J, Perry JR, Platou CG, Potter S, Rehnberg E, Robertson N, Sivapalaratnam S, Stancakova A, Stirrups K, Thorleifsson G, Tikkanen E, Wood AR, Almgren P, Atalay M, Benediktsson R, Bonnycastle LL, Burtt N, Carey J, Charpentier G, Crenshaw AT, Doney AS, Dorkhan M, Edkins S, Emilsson V, Eury E, Forsen T, Gertow K, Gigante B, Grant GB, Groves CJ, Guiducci C, Herder C, Hreidarsson AB, Hui J, James A, Jonsson A, Rathmann W, Klopp N, Kravic J, Krjutskov K, Langford C, Leander K, Lindholm E, Lobbens S, Mannisto S, Mirza G, Muhleisen TW, Musk B, Parkin M, Rallidis L, Saramies J, Sennblad B, Shah S, Sigurethsson G, Silveira A, Steinbach G, Thorand B, Trakalo J, Veglia F, Wennauer R, Winckler W, Zabaneh D, Campbell H, van Duijn C, Uitterlinden AG, Hofman A, Sijbrands E, Abecasis GR, Owen KR, Zeggini E, Trip MD, Forouhi NG, Syvanen AC, Eriksson JG, Peltonen L, Nothen MM, Balkau B, Palmer CN, Lyssenko V, Tuomi T, Isomaa B, Hunter DJ, Qi L, Wellcome Trust Case Control C, Meta-Analyses of G, Insulin-related traits Consortium I, Genetic Investigation of ATC, Asian Genetic Epidemiology Network-Type 2 Diabetes C, South Asian Type 2 Diabetes C, Shuldiner AR, Roden M, Barroso I, Wilsgaard T, Beilby J, Hovingh K, Price JF, Wilson JF, Rauramaa R, Lakka TA, Lind L, Dedoussis G, Njolstad I, Pedersen NL, Khaw KT, Wareham NJ, Keinanen-Kiukaanniemi SM, Saaristo TE, Korpi-Hyovalti E, Saltevo J, Laakso M, Kuusisto J, Metspalu A, Collins FS, Mohlke KL, Bergman RN, Tuomilehto J, Boehm BO, Gieger C, Hveem K, Cauchi S, Froguel P, Baldassarre D, Tremoli E, Humphries SE, Saleheen D, Danesh J, Ingelsson E, Ripatti S, Salomaa V, Erbel R, Jockel KH, Moebus S, Peters A, Illig T, de Faire U, Hamsten A, Morris AD, Donnelly PJ, Frayling TM, Hattersley AT, Boerwinkle E, Melander O, Kathiresan S, Nilsson PM, Deloukas P, Thorsteinsdottir U, Groop LC, Stefansson K, Hu F, Pankow JS, Dupuis J, Meigs JB, Altshuler D, Boehnke M, McCarthy MI, Replication DIG, Meta-analysis C: Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature genetics 2012;44:981-990

40. Replication DIG, Meta-analysis C, Asian Genetic Epidemiology Network Type 2 Diabetes C, South Asian Type 2 Diabetes C, Mexican American Type 2 Diabetes C, Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples C, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J, Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyovalti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Magi R, Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Muhleisen TW, Muller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stancakova A, Stefansson K, Steinbach G, Steinthorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvanen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP: Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nature genetics 2014;46:234-244

41. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JR, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, Bottcher Y, Bouchard C, Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, Clarke R, Collins FS, Corbaton-Anchuelo A, Couper D, de Faire U, Dedoussis GV, Deloukas P, Dimitriou M, Egan JM, Eiriksdottir G, Erdos MR, Eriksson JG, Eury E, Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks PW, Frayling TM, Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, Gudnason V, Hallmans G, Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun MA, Johnson PC, Jukema JW, Jula A, Kao WH, Kaprio J, Kardia SL, Keinanen-Kiukaanniemi S, Kivimaki M, Kolcic I, Kovacs P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka T, Lannfelt L, Lathrop GM, Launer LJ, Leander K, Li G, Lind L, Lindstrom J, Lobbens S, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Marmot M, Meneton P, Mohlke KL, Mooser V, Morken MA, Miljkovic I, Narisu N, O'Connell J, Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek O, Pramstaller PP, Province MA, Raikkonen K, Rauramaa R, Rehnberg E, Rice K, Rotter JI, Rudan I, Ruokonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, Saxena R, Schwarz P, Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, Sijbrands EJ, Siscovick DS, Smit JH, Small KS, Smith NL, Smith AV, Stancakova A, Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tonjes A, Tuomilehto J, Trompet S, Uitterlinden AG, Uusitupa M, Vikstrom M, Vitart V, Vohl MC, Voight BF, Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild SH, Willems SM, Willemsen G, Wilson JF, Witteman JC, Wright AF, Yaghootkar H, Zelenika D, Zemunik T, Zgaga L, Replication DIG, Meta-analysis C, Multiple Tissue Human Expression Resource C, Wareham NJ, McCarthy MI, Barroso I, Watanabe RM, Florez JC, Dupuis J, Meigs JB, Langenberg C: A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature genetics 2012;44:659-669

42. Prasad RB, Lessmark A, Almgren P, Kovacs G, Hansson O, Oskolkov N, Vitai M, Ladenvall C, Kovacs P, Fadista J, Lachmann M, Zhou Y, Sonestedt E, Poon W, Wollheim CB, Orho-Melander M, Stumvoll M, Tuomi T, Paabo S, Koranyi L, Groop L: Excess maternal transmission of variants in the THADA gene to offspring with type 2 diabetes. Diabetologia 2016;59:1702-1713

43. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, Replication DIG, Meta-analysis C, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJ, Penninx BW, Hofman A, Oostra BA, Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nature genetics 2012;44:991-1005

44. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C, Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM, Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martinez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J, Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stancakova A, Stirrups K, Swift AJ, Syvanen AC, Tuomi T, van 't Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B, Consortium D, Consortium G, Mu TC, Consortium CA, Consortium CD, Ongen H, Malarstig A, Hopewell JC, Saleheen D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Rios M, Ferrannini E, Forsen TJ, Clarke R, Franzosi MG, Seedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M, Dermitzakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V, Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC: Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 2011;60:2624-2634

45. Gjesing AP, Ribel-Madsen R, Harder MN, Eiberg H, Grarup N, Jorgensen T, Ekstrom CT, Pedersen O, Hansen T: Genetic and phenotypic correlations between surrogate measures of insulin release obtained from OGTT data. Diabetologia 2015;58:1006-1012

46. Stoffers DA, Ferrer J, Clarke WL, Habener JF: Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nature genetics 1997;17:138-139

47. Heni M, Ketterer C, Hart LM, Ranta F, van Haeften TW, Eekhoff EM, Dekker JM, Boomsma DI, Nijpels G, Kramer MH, Diamant M, Simonis-Bik AM, Heine RJ, de Geus EJ, Schafer SA, Machicao F, Ullrich S, Thamer C, Stefan N, Staiger H, Haring HU, Fritsche A: The impact of genetic variation in the G6PC2 gene on insulin secretion depends on glycemia. The Journal of clinical endocrinology and metabolism 2010;95:E479-484

48. Sparso T, Andersen G, Albrechtsen A, Jorgensen T, Borch-Johnsen K, Sandbaek A, Lauritzen T, Wasson J, Permutt MA, Glaser B, Madsbad S, Pedersen O, Hansen T: Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middle-aged people with normal and abnormal glucose regulation. Diabetologia 2008;51:1646-1652

49. da Silva Xavier G, Mondragon A, Sun G, Chen L, McGinty JA, French PM, Rutter GA: Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia 2012;55:2667-2676

50. McCarthy MI, Rorsman P, Gloyn AL: TCF7L2 and diabetes: a tale of two tissues, and of two species. Cell metabolism 2013;17:157-159

51. Nobrega MA: TCF7L2 and glucose metabolism: time to look beyond the pancreas. Diabetes 2013;62:706-708

52. Mitchell RK, Mondragon A, Chen L, McGinty JA, French PM, Ferrer J, Thorens B, Hodson DJ, Rutter GA, Da Silva Xavier G: Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell mass. Human molecular genetics 2015;24:1390-1399

53. Boj SF, van Es JH, Huch M, Li VS, Jose A, Hatzis P, Mokry M, Haegebarth A, van den Born M, Chambon P, Voshol P, Dor Y, Cuppen E, Fillat C, Clevers H: Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012;151:1595-1607

54. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjogren M, Ling C, Eriksson KF, Lethagen AL, Mancarella R, Berglund G, Tuomi T, Nilsson P, Del Prato S, Groop L: Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. The Journal of clinical investigation 2007;117:2155-2163

55. Schafer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, t Hart LM, Nijpels G, van Haeften TW, Haring HU, Fritsche A: Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007;50:2443-2450

56. Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschritter O, Staiger H, Stefan N, Haring HU, Fritsche A: Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008;51:597-601

57. Loos RJ, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, Ong KK, O'Rahilly S, Wareham NJ: TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007;56:1943-1947

58. Jonsson A, Ladenvall C, Ahluwalia TS, Kravic J, Krus U, Taneera J, Isomaa B, Tuomi T, Renstrom E, Groop L, Lyssenko V: Effects of common genetic variants associated with type 2 diabetes and glycemic traits on alpha- and beta-cell function and insulin action in humans. Diabetes 2013;62:2978-2983

59. Cho YS, Chen CH, Hu C, Long J, Ong RT, Sim X, Takeuchi F, Wu Y, Go MJ, Yamauchi T, Chang YC, Kwak SH, Ma RC, Yamamoto K, Adair LS, Aung T, Cai Q, Chang LC, Chen YT, Gao Y, Hu FB, Kim HL, Kim S, Kim YJ, Lee JJ, Lee NR, Li Y, Liu JJ, Lu W, Nakamura J, Nakashima E, Ng DP, Tay WT, Tsai FJ, Wong TY, Yokota M, Zheng W, Zhang R, Wang C, So WY, Ohnaka K, Ikegami H, Hara K, Cho YM, Cho NH, Chang TJ, Bao Y, Hedman AK, Morris AP, McCarthy MI, Consortium D, Mu TC, Takayanagi R, Park KS, Jia W, Chuang LM, Chan JC, Maeda S, Kadowaki T, Lee JY, Wu JY, Teo YY, Tai ES, Shu XO, Mohlke KL, Kato N, Han BG, Seielstad M: Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nature genetics 2012;44:67-72

60. Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, Chang CT, Wang TY, Chen RH, Shiu CF, Liu YM, Chang CC, Chen P, Chen CH, Fann CS, Chen YT, Wu JY: A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS genetics 2010;6:e1000847

**Table 1.** Type 2 diabetes risk alleles associated with lower first phase insulin response, AIR and or peak insulin (*P*<0.05), from a total of 76 analysed.Betas represent per allele effects in standard deviations. Associations reaching Bonferroni equivalents of *P*<0.05 are emboldened.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | **Peak insulin** | | | **Acute insulin response** | | |
| **Locus** | **OGTT/fasting\*** | **Lead SNP** | **Chr**† | **Position**‡ | **Risk Allele** | **Beta**§ | **SE** | **P-value** | **Beta**§ | **SE** | **P-value** |
| ***MTNR1B*** | **HG (1,2)** | **rs10830963** | **11** | **92,708,710** | **G** | **-0.235** | **0.023** | **1.34E-24** | **-0.218** | **0.023** | **3.65E-21** |
| ***CDKAL1*** | **BC (1,2)** | **rs7756992** | **6** | **20,679,709** | **G** | **-0.152** | **0.022** | **1.50E-12** | **-0.131** | **0.022** | **1.45E-09** |
| ***HNF1A*** | **UC (1,2)** | **rs12427353** | **12** | **121,426,901** | **G** | **-0.141** | **0.029** | **1.07E-06** | **-0.136** | **0.029** | **3.15E-06** |
| ***IGF2BP2*** | **UC** | **rs4402960** | **3** | **185,511,687** | **T** | **-0.101** | **0.022** | **4.90E-06** | **-0.091** | **0.022** | **4.65E-05** |
| ***TCF7L2*** | **BC (1)** | **rs7903146** | **10** | **114,758,349** | **T** | **-0.105** | **0.024** | **7.39E-06** | **-0.103** | **0.024** | **1.43E-05** |
| ***ARAP1 (CENTD2)*** | **PROINS (2)** | **rs1552224** | **11** | **72,433,098** | **A** | **-0.128** | **0.030** | **1.92E-05** | **-0.140** | **0.030** | **3.54E-06** |
| ***SLC30A8*** | **BC (1)** | **rs3802177** | **8** | **118,185,025** | **G** | **-0.089** | **0.022** | **5.88E-05** | **-0.090** | **0.022** | **5.94E-05** |
| ***ADCY5*** | **BC (2)** | **rs11717195** | **3** | **123,082,398** | **T** | **-0.092** | **0.023** | **8.43E-05** | -0.078 | 0.023 | 8.33E-04 |
| ***KCNQ1*** | **UC (1,2)** | **rs163184** | **11** | **2,847,069** | **G** | **-0.075** | **0.020** | **1.52E-04** | **-0.082** | **0.020** | **3.73E-05** |
| *C2CD4A* | N/A (1,2) | rs7163757 | 15 | 62,391,608 | C | -0.072 | 0.022 | 8.05E-04 | -0.071 | 0.022 | 9.34E-04 |
| *HHEX/IDE* | BC (1) | rs1111875 | 10 | 94,462,882 | C | -0.061 | 0.020 | 0.003 | -0.058 | 0.020 | 0.005 |
| ***CDKN2A/B*** | **BC (1)** | **rs10811661** | **9** | **22,134,094** | **T** | -0.087 | 0.029 | 0.003 | **-0.102** | **0.030** | **6.00E-04** |
| *FAF1* | N/A | rs17106184 | 1 | 50,909,985 | G | -0.104 | 0.039 | 0.008 | -0.091 | 0.039 | 0.020 |
| *PTPRD* | N/A (1) | rs17584499 | 9 | 8,879,118 | T | -0.063 | 0.027 | 0.020 | -0.062 | 0.027 | 0.023 |
| *PROX1* | BC | rs2075423 | 1 | 214,154,719 | G | -0.050 | 0.022 | 0.021 | -0.060 | 0.022 | 0.006 |
| *AP3S2* | N/A (2) | rs2028299 | 15 | 90,374,257 | C | -0.057 | 0.026 | 0.026 | -0.052 | 0.026 | 0.045 |
| *HNF1B* | UC (1) | rs4430796 | 17 | 36,098,040 | G | -0.045 | 0.022 | 0.039 | -0.066 | 0.022 | 0.003 |
| *MAEA* | N/A (2) | rs6815464 | 4 | 1,309,901 | C | -0.059 | 0.031 | 0.060 | -0.063 | 0.031 | 0.043 |
| *KCNK16* | N/A | rs1535500 | 6 | 39,284,050 | T | -0.041 | 0.022 | 0.060 | -0.045 | 0.022 | 0.041 |
| *DGKB* | BC | rs17168486 | 7 | 14,898,282 | T | -0.044 | 0.024 | 0.061 | -0.050 | 0.024 | 0.034 |
| *LPP* | N/A | rs6808574 | 3 | 187,740,523 | C | -0.039 | 0.023 | 0.090 | -0.048 | 0.023 | 0.040 |
| \*Association (*P*<0.05) with OGTT based measure of insulin secretion or fasting glucose, as reported by (1) Prokopenko et al (CIR), (2) this study (CIRBMI+SI adjusted) and as Dimas et al classified: HG=hyperglycemic, BC=beta cell ,UC=unclassified, N/A=not available in Dimas et al; indicated according to their classification HG: hyperglycaemic reduced beta-cell function after glucose stimulation, BC: defective beta-cell function, PROINS: decreased proinsulin, UC: unclassified. †Chromosome. ‡Base-pair position build-37. §Betas represent standard deviation effects per risk allele. | | | | | | | | | | | |

**Table 2**. Fasting glucose raising alleles associated with lower first phase insulin response but not identified as a type 2 diabetes risk allele. Betas represent per allele effects in standard deviations. Associations reaching Bonferroni equivalents of *P*<0.05 are emboldened.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | **Peak insulin** | | | **Acute insulin response** | | |
| **Locus** | **Lead SNP** | **Chr**\* | **Position**† | **Effect Allele** | **Beta**‡ | **SE** | **P-value** | **Beta**‡ | **SE** | **P-value** |
| ***PDX1*** | **rs11619319** | **13** | **28,487,599** | **G** | **-0.106** | **0.023** | **2.54E-06** | **-0.115** | **0.023** | **3.74E-07** |
| ***DNLZ*** | **rs3829109** | **9** | **139,256,766** | **G** | **-0.088** | **0.022** | **5.77E-05** | **-0.089** | **0.022** | **4.83E-05** |
| *CRY2* | rs11607883 | 11 | 45,839,709 | G | -0.047 | 0.020 | 0.017 | -0.055 | 0.020 | 0.005 |
| *GLIS3* | rs10814916 | 9 | 4,293,150 | C | -0.044 | 0.020 | 0.029 | -0.046 | 0.020 | 0.023 |
| *PROX1* | rs340874 | 1 | 214,159,256 | C | -0.041 | 0.020 | 0.039 | -0.056 | 0.020 | 0.006 |
| *ADRA2A* | rs11195502 | 10 | 113,039,667 | C | -0.069 | 0.035 | 0.052 | -0.079 | 0.036 | 0.026 |
| \*Chromosome. †Base-pair position build-37. ‡Betas represent standard deviation effects per risk allele. | | | | | | | | | | |

**Table 3**. Known type 2 diabetes and glycaemic trait variants associated with insulin secretion rate (ISR). N = 1,268. Betas represent per allele effects in standard deviations. Associations reaching Bonferroni equivalents of *P*<0.05 are emboldened.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  | **ISR** | | |
| **Locus** | **Trait\*** | **Classification**† | **Association Pattern**‡ | **Lead SNP** | **Chr**§ | **Position**|| | **Risk Allele** | **Beta**¶ | **SE** | **P-value** |
| ***MTNR1B*** | **T2D / FG** | **HG** | **1,2,3,4** | **rs10830963** | **11** | **92,708,710** | **G** | **-0.232** | **0.043** | **9.01E-08** |
| ***CDKAL1*** | **T2D / FG** | **BC** | **1,2,3,4** | **rs7756992** | **6** | **20,679,709** | **G** | **-0.232** | **0.045** | **1.91E-07** |
| ***CDKN2A/B*** | **T2D / FG** | **BC** | **1,2,3** | **rs10811661** | **9** | **22,134,094** | **T** | **-0.224** | **0.054** | **3.46E-05** |
| *WFS1* | T2D | UC |  | rs4458523 | 4 | 6,289,986 | G | -0.124 | 0.041 | 0.003 |
| *SLC30A8* | T2D / FG | BC | 1,2,3 | rs3802177 | 8 | 118,185,025 | G | -0.122 | 0.044 | 0.006 |
| *TMPRSS6* | HbA1C | N/A |  | rs855791 | 22 | 37,462,936 | A | -0.114 | 0.042 | 0.006 |
| *PDX1* | FG | N/A | 1,2,4 | rs11619319 | 13 | 28,487,599 | G | -0.129 | 0.049 | 0.008 |
| *ANK1* | T2D | N/A | 3 | rs516946 | 8 | 41,519,248 | C | -0.113 | 0.048 | 0.018 |
| *HHEX/IDE* | T2D | BC | 1,2,3 | rs1111875 | 10 | 94,462,882 | C | -0.086 | 0.041 | 0.037 |
| *IGF2BP2* | T2D / FG | UC | 1,2 | rs4402960 | 3 | 185,511,687 | T | -0.091 | 0.044 | 0.037 |
| \*Associated trait: T2D=type 2 diabetes, FG=fasting glucose; †Classification by Dimas et al: HG=hyperglycemic, BC=beta cell ,UC=unclassified, N/A=not available in Dimas et al; ‡Code relating to significance of association across phenotypes and datasets: 1=associated at *P*<0.05 with peak insulin in our data, 2=associated at P<0.05 with acute insulin response in our data, 3=associated with CIR in Prokopenko et al., 4=associated at *P*<0.05 with CIRBMI+SI adjustment in our data. §Chromosome. ||Base-pair position build-37; ¶Betas represent standard deviation effects per effect allele. | | | | | | | | | | |

**Table 4.** Apparently paradoxical associations between known glycaemic variants and first phase insulin secretion. Betas represent per allele effects in standard deviations. Associations reaching Bonferroni equivalents of *P*<0.05 are emboldened.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | **Peak insulin** | | | | **Acute insulin response** | | | | **DI**¶ |
| **Locus** | **Known Trait\*** | **Lead SNP** | **Chr**† | **Position**‡ | **Effect**  **Allele** | **Beta**§ | **SE** | **P-value** | **P-value (BMI+SI)**|| | **Beta**§ | **SE** | **P-value** | **P-value (BMI+SI)**|| | **P-value**  **(BMI)** |
|
| *G6PC2* | FG | rs560887 | 2 | 169,763,148 | C | **0.061** | **0.024** | **0.012** | **6.70E-04** | **0.074** | **0.024** | **0.002** | **8.25E-05** | **1.1E-04** |
| *GRB10* | FG | rs6943153 | 7 | 50,791,579 | T | 0.069 | 0.021 | 8.47E-04 | 0.003 | 0.066 | 0.021 | 0.002 | 0.003 | 0.018 |
| *OR4S1*/*PTPRJ#* | FG | rs1483121 | 11 | 48,333,360 | G | 0.114 | 0.036 | 0.002 | 0.001 | 0.111 | 0.036 | 0.002 | 0.002 | 0.033 |
| *MADD* | Fproinsulin | rs10501320 | 11 | 47,293,799 | G | 0.084 | 0.029 | 0.003 | **4.12E-04** | 0.090 | 0.029 | 0.002 | **4.82E-04** | 0.252 |
| *PCSK1* | Fproinsulin | rs6235 | 5 | 95,728,898 | G | **0.096** | **0.025** | **1.09E-04** | 0.002 | **0.104** | **0.025** | **2.98E-05** | **4.35E-04** | 0.013 |
| *PPARG* | FI-adjBMI | rs17036328 | 3 | 12,390,484 | T | 0.096 | 0.029 | 9.42E-04 | 0.012 | **0.110** | **0.029** | **1.64E-04** | 0.005 | 0.302 |
| *ARAP1* | Fproinsulin | rs11603334 | 11 | 72,432,985 | A | **0.128** | **0.030** | **1.96E-05** | 8.55E-04 | **0.140** | **0.030** | **3.60E-06** | **7.45E-05** | 0.027 |
| *FTO* | BMI | rs1421085 | 16 | 53,800,954 | C | 0.038 | 0.022 | 0.084 | 0.688 | 0.048 | 0.022 | 0.031 | 0.951 | 0.253 |
| *GCC1* | T2D | rs6467136 | 7 | 127,164,958 | G | 0.052 | 0.022 | 0.015 | 0.024 | 0.050 | 0.022 | 0.021 | 0.033 | 0.068 |
| *NOTCH2* | T2D | rs10923931 | 1 | 120,517,959 | T | 0.066 | 0.032 | 0.039 | 0.057 | 0.053 | 0.032 | 0.1 | 0.212 | 0.272 |
| \*Trait previously associated with SNP. †Chromosome. ‡Base-pair position build-37. §Betas represent standard deviation effects per effect allele.||P-value after BMI+SI adjustment. FG=fasting glucose, Fproinsulin=fasting proinsulin,T2D=type 2 diabetes, FI-adjBMI=fasting insulin adjusted for BMI ¶DI = Disposition Index adjusted for BMI; #*PTPRJ* is the nearest non-olfactory receptor gene in the locus. | | | | | | | | | | | | | | |

**Table 5.** Apparently paradoxical associations between known glycaemic variants and insulin secretion rate. Betas represent per allele effects in standard deviations.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  | **ISR** | | | | **DI** |
| **Locus** | **Trait\*** | **Classification**† | **Association**  **Pattern**‡ | **Lead SNP** | **Chr**§ | **Position**|| | **Risk**  **Allele** | **Beta**¶ | **SE** | **P-value** | **P-value**  **(BMI)#** | **P-value**  **(BMI)#** |
| *GRB10* | FG | N/A | 3 | rs6943153 | 7 | 50,791,579 | T | 0.143 | 0.045 | 0.001 | 8.25E-04 | 0.018 |
| *HMG20A* | T2D | N/A |  | rs7178572 | 15 | 77,747,190 | G | 0.136 | 0.043 | 0.001 | 0.002 | 0.969 |
| *OR4S1*/*PTPRJ* | FG | N/A |  | rs1483121 | 11 | 48,333,360 | G | 0.232 | 0.086 | 0.007 | 0.003 | 0.033 |
| *PCSK1* | Fproinsulin | N/A |  | rs6235 | 5 | 95,728,898 | G | 0.108 | 0.044 | 0.015 | 0.02 | 0.013 |
| *TMEM163* | T2D | N/A | 2 | rs6723108 | 2 | 135,479,980 | T | 0.094 | 0.042 | 0.024 | 0.03 | 0.854 |
| *ADAMTS9* | T2D | UC |  | rs6795735 | 3 | 64,705,365 | C | 0.088 | 0.040 | 0.028 | 0.02 | 0.428 |
| *IKBKAP* | FG | N/A |  | rs16913693 | 9 | 111,680,359 | T | 0.246 | 0.117 | 0.036 | 0.05 | 0.404 |
| *KLHDC5* | T2D | N/A |  | rs10842994 | 12 | 27,965,150 | C | 0.104 | 0.050 | 0.038 | 0.04 | 0.291 |
| *TET2* | FI | N/A |  | rs9884482 | 4 | 106,081,636 | C | 0.082 | 0.041 | 0.048 | 0.03 | 0.788 |
| \*Associated trait: FG=fasting glucose,Fproinsulin=fasting proinsulin,T2D=type 2 diabetes, FG=fasting glucose,FI=fasting insulin; †Classification by Dimas et al: UC=unclassified, N/A=not available; ‡Code relating to significance of association across phenotypes and datasets: 1=associated at *P*<0.05 with peak insulin in our data, 2=associated at *P*<0.05 with acute insulin response in our data, 3=associated with CIR in Prokopenko et al., 4=associated at *P*<0.05 with CIRBMI+SI adj in our data. §Chromosome. ||Base-pair position build-37. ¶Betas represent standard deviation effects per effect allele; **#**P-value after ISR adjustment for BMI. | | | | | | | | | | | | |

**FIGURE LEGENDS**

**Figure 1**. IVGTT (peak insulin response) based first phase insulin secretion versus OGTT based insulin secretion (corrected insulin response) for known type 2 diabetes variants. Units = standard deviation. Orange circles = SNP associated with both peak insulin response and CIR (P<0.05); green circles = SNP associated with peak insulin response (P<0.05); blue circles = SNP associated with CIR (P<0.05), yellow circles = SNP not associated with either trait (P>0.05).

**Figure 2.** Insulin secretion rate versus OGTT based insulin secretion (corrected insulin response) for known type 2 diabetes variants. Units = standard deviation. Orange circles = SNP associated with both ISR and CIR (P<0.05); green circles = SNP associated with ISR (P<0.05); blue circles = SNP associated with CIR (P<0.05), yellow circles = SNP not associated with either trait (P>0.05).

**Figure 3.** IVGTT (peak insulin response) based first phase insulin secretion versus type 2 diabetes risk (OR = Odds ratio), for known type 2 diabetes variants. Y-axis units = standard deviation. (Type 2 diabetes odds ratios are from Morris et al([39](#_ENREF_39)), and some were reported from previous studies of East Asians([59](#_ENREF_59); [60](#_ENREF_60)). Orange circles = SNP associated with both peak insulin response and type 2 diabetes risk (P<0.05); green circles = SNP associated with peak insulin response (P<0.05); blue circles = SNP associated with type 2 diabetes risk (P<0.05), yellow circles = SNP not associated with either trait (P>0.05).

**Figure 4.** Insulin secretion rate versus type 2 diabetes risk for known type 2 diabetes variants. Y-axis units = standard deviation. Orange circles = SNP associated with both ISR and type 2 diabetes risk (P<0.05); green circles = SNP associated with ISR (P<0.05); blue circles = SNP associated with type 2 diabetes risk (P<0.05), yellow circles = SNP not associated with either trait (P>0.05).